473 related articles for article (PubMed ID: 33240283)
1. Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.
Li Z; Deng J; Sun J; Ma Y
Front Immunol; 2020; 11():595207. PubMed ID: 33240283
[TBL] [Abstract][Full Text] [Related]
2. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
3. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
4. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes.
Liu P; Ye M; Wu Y; Wu L; Lan K; Wu Z
Cancer Med; 2023 Feb; 12(3):3201-3221. PubMed ID: 35908281
[TBL] [Abstract][Full Text] [Related]
6. The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors.
Takkenkamp TJ; Jalving M; Hoogwater FJH; Walenkamp AME
Endocr Relat Cancer; 2020 Sep; 27(9):R329-R343. PubMed ID: 32590336
[TBL] [Abstract][Full Text] [Related]
7. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
8. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
9. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
10. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.
Hu-Lieskovan S; Malouf GG; Jacobs I; Chou J; Liu L; Johnson ML
Future Oncol; 2021 Apr; 17(11):1401-1439. PubMed ID: 33475012
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoints in the tumor microenvironment.
Toor SM; Sasidharan Nair V; Decock J; Elkord E
Semin Cancer Biol; 2020 Oct; 65():1-12. PubMed ID: 31265893
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
13. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
14. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.
Oladejo M; Paulishak W; Wood L
Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110
[TBL] [Abstract][Full Text] [Related]
15. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
16. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
17. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
19. The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.
Shi MY; Liu HG; Chen XH; Tian Y; Chen ZN; Wang K
Front Immunol; 2022; 13():1088886. PubMed ID: 36703971
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]